Saeki S, Nishiyama M, Toge T
Department of Surgical Oncology, Hiroshima University, Japan.
Hiroshima J Med Sci. 1995 Sep;44(3):55-63.
We studied a selective enhancement of the mitomycin C (MMC)-induced antitumor effect focusing on the intracellular metabolism by NAD(P)H:quinone oxidoreductase (DT-diaphorase, DTD). The level of cellular DTD activity related well to the degree of MMC-induced DNA total cross links and cell growth inhibition in human cancer cell lines, KB, PH101, SH101 and K562. A DTD inhibitor, dicoumarol (DIC) or flavin adenine dinucleotide (FAD), inhibited the MMC-induced DNA damage and cytotoxicity at a non-toxic concentration. The DTD-mediated MMC activation was pH-dependent, and highest at pH 6 and lowest at pH 8. Although an inverse relationship appeared to exist between DTD activity and MMC efficacy in human xenografts implanted into nude mice and 9 fresh human tumor specimens, the investigation in 3 culture cells, HEC-46, HCC-48 and HCC-50, established from those xenografts, showed that DTD activated MMC in a pH-dependent manner as well as the other cell lines. Significant tumor pH reduction from 7.1 to 6.7 by continuous glucose infusion also increased the MMC-induced tumor growth inhibition in the human tumor xenografts. Thus, we conclude that bioreductive activation by DTD in a pH-dependent manner may be of key importance in the MMC-induced antitumor effect and that an increased MMC efficacy at a reduced pH caused by hyperglycemia may be applied to clinical use as a new manipulation for a biochemical modulation of MMC.
我们研究了丝裂霉素C(MMC)诱导的抗肿瘤作用的选择性增强,重点关注烟酰胺腺嘌呤二核苷酸磷酸(NAD(P)H):醌氧化还原酶(DT-黄递酶,DTD)的细胞内代谢。在人癌细胞系KB、PH101、SH101和K562中,细胞DTD活性水平与MMC诱导的DNA总交联程度和细胞生长抑制程度密切相关。一种DTD抑制剂双香豆素(DIC)或黄素腺嘌呤二核苷酸(FAD),在无毒浓度下可抑制MMC诱导的DNA损伤和细胞毒性。DTD介导的MMC激活呈pH依赖性,在pH 6时最高,在pH 8时最低。尽管在植入裸鼠的人异种移植物和9个新鲜人肿瘤标本中,DTD活性与MMC疗效之间似乎存在负相关,但对从这些异种移植物建立的3种培养细胞HEC-46、HCC-48和HCC-50的研究表明,DTD以pH依赖性方式激活MMC,与其他细胞系一样。通过持续输注葡萄糖使肿瘤pH值从7.1显著降低至6.7,也增强了MMC对人肿瘤异种移植物生长的抑制作用。因此,我们得出结论,DTD以pH依赖性方式进行的生物还原激活可能在MMC诱导的抗肿瘤作用中起关键作用,并且高血糖导致的pH值降低时MMC疗效的增加可作为MMC生化调节的一种新操作应用于临床。